The clamour for a price review of Ozempic on the NHS grows louder as new data reveals a stark transatlantic divide. Canadians can obtain generic semaglutide at a fraction of the cost paid by American patients, with British taxpayers caught in the middle. This is not just about fairness; it is about market efficiency and fiscal responsibility.
The figures are stark. In Canada, a month's supply of the generic version costs around £100, thanks to the country's Patented Medicine Prices Review Board, which caps drug prices. Across the border, Americans face prices exceeding £1,000 for the same medication, driven by a fragmented healthcare system where private insurers and pharmacy benefit managers negotiate in opaque deals. The UK sits uncomfortably between these extremes. While the NHS has negotiated discounts for branded Ozempic, the price remains significantly higher than Canada's generic benchmark. The question is: why?
The answer lies in intellectual property and market dynamics. Novo Nordisk's patent on semaglutide has not expired in the UK. However, Canada's system allows for compulsory licensing and price controls that undercut monopoly pricing. The UK's NHS operates a different model: it relies on voluntary schemes with pharmaceutical companies, such as the 2019 Voluntary Scheme for Branded Medicines, which caps growth in spending but does not directly control individual drug prices. The result is that the NHS pays about £70 per month for branded Ozempic, a price that looks reasonable compared to the US but exorbitant when set against Canada's generic cost.
Enter the British politicians. Labour MPs have tabled parliamentary questions demanding that the Department of Health and Social Care explain why UK patients cannot access cheaper alternatives. The argument is simple: if Canada can procure generic semaglutide for £100, why cannot the NHS with its 65 million citizens do the same? The Treasury, too, is watching. With the NHS facing a £12 billion funding gap by 2025, every pound saved on drugs is a pound that can be spent on frontline services.
But this is not without complications. The UK's exit from the European Union has given Westminster greater freedom to negotiate drug prices, but it has also weakened its bargaining position. The UK no longer benefits from the EU's bulk purchasing power. Moreover, the government's 'Life Sciences Vision' aims to attract pharmaceutical investment, and aggressive price controls could deter companies from launching new drugs here. It is a delicate balancing act between access and innovation.
Investors are already pricing in the risk. Shares in Novo Nordisk have wobbled on the news, reflecting fears that other countries may follow Canada's lead. If the UK forces a price review, it could set a precedent for other European nations, eroding the high margins that make obesity drugs such a lucrative market. The market expects that any NHS price cut will be modest, given the political sensitivity of the 'obesity crisis'. However, the generic wave is coming. Semaglutide patents will expire in the early 2030s, and when they do, prices will plummet. The question is whether the NHS will wait or act now.
Capital flight is another concern. Global wealth is mobile, and a perception that the UK is turning against pharmaceutical innovation could push investment towards Switzerland or the United States. The Life Sciences sector contributes £90 billion to the UK economy, and any signal that the government is hostile to high drug prices might spook investors. Yet the public mood is unforgiving. The cost-of-living crisis has made voters hyper-aware of price disparities, and 'NHS price gouging' is a potent political narrative.
What should the Chancellor do? The prudent path is a targeted review of Ozempic pricing, not a wholesale crackdown. The NHS should leverage its buying power to secure discounts akin to those in Canada, perhaps through a 'most favoured nation' clause linking UK prices to the lowest among comparable countries. This would be a market-friendly solution that does not alienate innovators. The alternative is to wait for generics, but that is a costly delay. In the battle against obesity and diabetes, time is money. The bottom line is that the UK cannot afford to pay more than necessary, especially when Canadians are showing us how it is done.
